2017 INTEREST Conference

2017年兴趣大会

基本信息

批准号：
9349001
负责人：
Guido Ferrari
金额：
$ 7万
依托单位：
DUKE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-04-13 至 2018-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9349001
关键词：
AIDS prevention Acquired Immunodeficiency Syndrome Acute Address Adolescent Adult Africa Africa South of the Sahara African Anti-Retroviral Agents Area Award Basic Science CD4 Lymphocyte Count Cameroon Career Choice Caring Central Africa Child Chronic Clinical Research Collaborations Communities Comorbidity Complement Country Development Diagnosis Doctor of Philosophy Early Diagnosis Eastern Africa Ebola virus Educational workshop Epidemic Event Exposure to Fostering Future Goals HIV HIV Seropositivity HIV-1 Head Health Health Care Research Health financing Healthcare Hepatitis Hepatitis C Human Resources Human immunodeficiency virus test Immune system Incidence Individual Infection Infection prevention Institutes International Intervention Investments Kenya Knowledge Leadership Malawi Measures Monitor Mozambique Oral Pathogenesis Patient Monitoring Patients Phase Physicians Policies Prevalence Prevention Prevention Research Prevention strategy Public Health Research Research Personnel Resources Scientist Senegal Services Southern Africa Tanzania Training Travel Treatment Step Trust Uganda Viral Viral Load result Viral load measurement Vocational Guidance Western Africa Work Zambia Zimbabwe base burden of illness clinical care cost effective effective therapy experience global health immune activation implementation science improved knowledge base mHealth meetings novel pathogen programs response scale up stem symposium transmission process treatment strategy

项目摘要

Abstract. The most recent UNAIDS estimates of the global burden of HIV are that 36.7 million people are living with HIV-1 infection worldwide and 25.5 million of them live in sub-Saharan Africa (UNAIDS Fact Sheet 2016). Moreover, 70% of new infections annually are occurring in the same region of the world (UNAIDS. How AIDS Changed Everything; 2015). Since 2010, HIV incidence has declined by 14% in eastern and southern Africa and by 8% in western and central Africa, while HIV prevalence continues to rise as more people access antiretroviral treatment. Although treatment is likely having an important impact on slowing HIV transmission, alone it will not turn the epidemic on its head. HIV prevention remains critical to stem the tide of HIV. The UNAIDS 90-90-90 targets for 2020 aim for 90% of people living with HIV knowing their HIV status, 90% of people who know their HIV-positive status being on antiretroviral treatment, and 90% of people on treatment having suppressed virus loads (UNAIDS. Fast- track: ending the AIDS epidemic by 2030; 2014). Current estimates for the African continent are that 29% of all those living with HIV have suppressed viral loads. Every step of the treatment cascade needs intensive investment: scaling up HIV testing access to diagnose those living with HIV, an immediate offer of antiretroviral treatment regardless of CD4 count, and retention in effective treatment to achieve viral suppression. Although there are many measures in place to tackle the HIV disease burden in Africa there remains much work to do in terms of training local physicians and scientists in regard to diagnosis, treatment, and management of individuals with HIV-1 infection, as well as in respect to evidence-informed public health responses and implementation science to determine the most cost-effective use of financial and human resources. The 2017 INTEREST Conference, known as the ‘African CROI’ brings together scientists involved in HIV treatment, pathogenesis, and prevention research in resource-limited settings in Africa to share pivotal findings, promote collaboration, and transfer experiences across several fields and many continents. A prominent group of international experts in the field of HIV launched this focused international scientific meeting in Africa in 2007. Since then, 10 successful annual meetings have been convened in Uganda, Senegal (twice), Zambia (twice), Mozambique, Tanzania, Kenya, Zimbabwe, and Cameroon. Planning and organization of the conference is overseen by the Amsterdam Institute of Global Health and Development. Catherine Hankins MD PhD chairs INTEREST’s international organizing committee (IOC) and is the Scientific Chair of INTEREST. The Local Chair for 2017 INTEREST conference is Sam Phiri MD PhD, Director of the Lighthouse Trust, Malawi. The organizers of the 2017 INTEREST Conference will pursue the following objectives: 1) To showcase cutting-edge knowledge in the fields of HIV pathogenesis, diagnosis, treatment, and prevention of HIV-1 infection. 2) To continue to foster the building of a community of African physicians and scientists who discuss implementing local solutions for the management of patients living with HIV-1 infection and for the prevention of HIV transmission. ! !

抽象的。联合国艾滋病规划署 (UNAIDS) 对全球艾滋病毒负担的最新估计是，有 3,670 万人感染艾滋病毒。全球 HIV-1 感染者，其中 2550 万人生活在撒哈拉以南非洲（联合国艾滋病规划署事实此外，70%的新增感染发生在世界同一地区（联合国艾滋病规划署。艾滋病如何改变一切；2015 年以来，艾滋病毒发病率下降了 14%）。东部和南部非洲增加了 8%，西部和中部非洲增加了 8%，而艾滋病毒感染率继续上升随着越来越多的人接受抗逆转录病毒治疗，这一数字会上升，尽管治疗可能具有重要意义。减缓艾滋病毒传播的影响，但仅靠它并不能彻底改变艾滋病毒的预防工作。联合国艾滋病规划署 2020 年 90-90-90 目标的目标是让 90% 的人受益。艾滋病毒感染者知道自己的艾滋病毒状况，90% 知道自己艾滋病毒呈阳性状况的人抗逆转录病毒治疗，90% 接受治疗的人病毒载量受到抑制（联合国艾滋病规划署。快速- 目标：到 2014 年结束艾滋病流行；目前非洲大陆的估计为 29%。的所有艾滋病毒感染者都已抑制了治疗级联的每一步所需的病毒载量。密集投资：扩大艾滋病毒检测范围以诊断艾滋病毒感染者，立即提供抗逆转录病毒治疗，无论 CD4 计数如何，并保留有效治疗以实现病毒治疗尽管非洲已经采取了许多措施来解决艾滋病毒疾病负担。在诊断方面培训当地医生和科学家方面仍有许多工作要做， HIV-1 感染者的治疗和管理，以及基于证据的公共卫生应对措施和实施科学，以确定最具成本效益的财政利用和人力资源。 2017 年 INTEREST 会议，被称为“非洲 CROI”，汇聚了参与其中的科学家在非洲资源有限的地区进行艾滋病毒治疗、发病机制和预防研究，以分享关键发现，促进合作，并在多个领域和许多领域转移经验艾滋病毒领域的一个著名国际专家小组发起了这一重点活动。 2007年在非洲举办国际科学会议。此后，已成功举办了10届年会在乌干达、塞内加尔（两次）、赞比亚（两次）、莫桑比克、坦桑尼亚、肯尼亚、津巴布韦和喀麦隆。会议的规划和组织由阿姆斯特丹全球研究所监督。健康与发展医学博士 Catherine Hankins 担任 INTEREST 国际组织主席委员会 (IOC) 并担任 INTEREST 科学主席 2017 年 INTEREST 当地主席。会议由马拉维灯塔信托基金主任 Sam Phiri MD 博士主持。 2017年INTEREST会议的组织者将追求以下目标： 1）展示艾滋病发病机制、诊断、治疗和预防 HIV-1 感染。 2) 继续促进非洲医生和科学家社区的建设讨论实施本地解决方案来管理 HIV-1 感染者感染和预防艾滋病毒传播。！！